{"id":"brm421-ophthalmic-solution","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a Phase 3 ophthalmic formulation, BRM421 is being developed for topical ocular administration. The specific molecular mechanism is not publicly disclosed in available sources, but ophthalmic solutions in clinical development typically target inflammatory pathways, mucin production, or aqueous tear film stability to address dry eye disease or related ocular surface conditions.","oneSentence":"BRM421 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:59.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease or ocular surface disease (presumed, based on ophthalmic formulation)"}]},"trialDetails":[{"nctId":"NCT07422389","phase":"","title":"BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency","status":"AVAILABLE","sponsor":"BRIM Biotechnology Inc.","startDate":"","conditions":"Limbal Stem Cell Deficiency (LSCD)","enrollment":""},{"nctId":"NCT07078955","phase":"PHASE2","title":"A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease","status":"NOT_YET_RECRUITING","sponsor":"BRIM Biotechnology Inc.","startDate":"2025-12","conditions":"Dry Eye Disease (DED), Keratoconjunctivitis Sicca","enrollment":99},{"nctId":"NCT05695781","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.","status":"COMPLETED","sponsor":"BRIM Biotechnology Inc.","startDate":"2023-02-27","conditions":"Dry Eye Disease","enrollment":740},{"nctId":"NCT04343287","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment","status":"COMPLETED","sponsor":"BRIM Biotechnology Inc.","startDate":"2020-01-15","conditions":"Dry Eye Syndrome","enrollment":220},{"nctId":"NCT03066219","phase":"PHASE2","title":"Safety and Efficacy of BRM421 for Dry Eye Syndrome","status":"COMPLETED","sponsor":"BRIM Biotechnology Inc.","startDate":"2017-02-07","conditions":"Dry Eye Syndrome","enrollment":157}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BRM421 Ophthalmic Solution","genericName":"BRM421 Ophthalmic Solution","companyName":"BRIM Biotechnology Inc.","companyId":"brim-biotechnology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BRM421 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms. Used for Dry eye disease or ocular surface disease (presumed, based on ophthalmic formulation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}